Biotest Balance Sheet Health
Financial Health criteria checks 3/6
Biotest has a total shareholder equity of €358.7M and total debt of €513.0M, which brings its debt-to-equity ratio to 143%. Its total assets and total liabilities are €1.1B and €743.2M respectively.
Key information
143.0%
Debt to equity ratio
€513.00m
Debt
Interest coverage ratio | n/a |
Cash | €85.00m |
Equity | €358.70m |
Total liabilities | €743.20m |
Total assets | €1.10b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BTTA.Y's short term assets (€522.0M) exceed its short term liabilities (€122.2M).
Long Term Liabilities: BTTA.Y's short term assets (€522.0M) do not cover its long term liabilities (€621.0M).
Debt to Equity History and Analysis
Debt Level: BTTA.Y's net debt to equity ratio (119.3%) is considered high.
Reducing Debt: BTTA.Y's debt to equity ratio has increased from 121% to 143% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BTTA.Y has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BTTA.Y is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24.4% per year.